Market Place
Sourcing Support
Biohaven Reports Positive Phase 1 Degrader Data, NDA Submission
16 Dec 2024 //
PR NEWSWIRE
Biohaven Presents Data On BHV-7000 For Epilepsy At AES 2024
06 Dec 2024 //
PR NEWSWIRE
Biohaven`s spinal muscular atrophy drug fails to meet study goal
26 Nov 2024 //
REUTERS
Biohaven Reports Q3 2024 Financial Results & Business Developments
12 Nov 2024 //
PR NEWSWIRE
Biohaven Closes Public Offering With Full Underwriters` Option
02 Oct 2024 //
PR NEWSWIRE
Biohaven Prices $250 Million Public Offering of Common Shares
01 Oct 2024 //
PR NEWSWIRE
Biohaven Achieves Topline Results in Study of Troriluzole in SCA
24 Sep 2024 //
PR NEWSWIRE
Biohaven To Discuss Topline Results in Spinocerebellar Ataxia
20 Sep 2024 //
PR NEWSWIRE
Biohaven Reports Q2 2024 Results And Business Developments
08 Aug 2024 //
PR NEWSWIRE
Pfizer to press pause on large M&A deals, CEO says
11 Jun 2024 //
FIERCE PHARMA
Biohaven Doses First Patient With Novel Trop-2 ADC BHV-1510
30 May 2024 //
PR NEWSWIRE
Biohaven Showcases Portfolio Pipeline Updates Across Multiple Therapy Areas
30 May 2024 //
PR NEWSWIRE
Biohaven’s autoimmune drug disappoints investors in study of healthy volunteers
29 May 2024 //
ENDPTS
Biohaven Q1 2024 Financials, Business Developments
09 May 2024 //
PR NEWSWIRE
Biohaven Offering Closes With Overallotment Exercised
22 Apr 2024 //
PR NEWSWIRE
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
18 Apr 2024 //
PR NEWSWIRE
Biohaven Proposed Public Offering of Common Shares
17 Apr 2024 //
PRESS RELEASE
Biohaven: 20 Presentations At AAN 2024, Business Updates
13 Apr 2024 //
PR NEWSWIRE
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results
29 Feb 2024 //
PRESS RELEASE
Apnimed hires Pfizer, Biohaven veteran as chief commercial officer
22 Jan 2024 //
ENDPTS
Biohaven Highlights Progress Across Innovative Portfolio
08 Jan 2024 //
PR NEWSWIRE
Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
PR NEWSWIRE
Biohaven Presents Expanded EEG and Safety Data for BHV-7000
01 Dec 2023 //
PR NEWSWIRE
Biohaven Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
PRESS RELEASE
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat
16 Oct 2023 //
PR NEWSWIRE
Biohaven Announces Closing of Public Offering
05 Oct 2023 //
PR NEWSWIRE
Biohaven Announces Proposed Public Offering Of Common Shares
02 Oct 2023 //
PRESS RELEASE
Biohaven Announces Pricing of $225 Million Public Offering of Common Shares
02 Oct 2023 //
PR NEWSWIRE
Why Biohaven Stock Is Skyrocketing Today
27 Sep 2023 //
FOOL
Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa
14 Sep 2023 //
PR NEWSWIRE
Biohaven Announces Positive Data from its EEG Biomarker Study of BHV-7000
05 Sep 2023 //
PR NEWSWIRE
Biohaven`s Taldefgrobep Alfa Receives EU Orphan Drug Designation
31 Jul 2023 //
PR NEWSWIRE
Biohaven Provides Preliminary EEG Data Update for Kv7 Platform
27 Jul 2023 //
PR NEWSWIRE
A blow for Biohaven as FDA refuses failed rare disease drug
27 Jul 2023 //
FIERCE BIOTECH
Why Biohaven Stock Caught Fire This Week
02 Jun 2023 //
FOOL
Biohaven Provides Overview of Clinical Progress, Regulatory Updates
31 May 2023 //
PRESS RELEASE
Biohaven Provides Overview of Clinical Progress at R&D Day
31 May 2023 //
PR NEWSWIRE
Biohaven Reports 1Q 2023 FYR and Reports Recent Business Developments
12 May 2023 //
PR NEWSWIRE
Biohaven Acquires Exclusive License for TYK2/JAK1 Inhibitor for Brain Disorders
22 Mar 2023 //
PR NEWSWIRE
Biohaven grabs TYK2/JAK1 drug for $20M to start, $950M on the line
22 Mar 2023 //
ENDPTS
Pfizer and Biohaven recall 4.2M Nurtec units on packaging flaw
16 Mar 2023 //
FIERCE PHARMA
Biohaven Announces Presentation at the ASENT Annual Meeting
14 Mar 2023 //
PR NEWSWIRE
Biohaven`s Taldefgrobep Alfa receives FDA Fast Track Designation
21 Feb 2023 //
CONTRACT PHARMA
Biohaven Ltd. Reports3Q 2022 Financial Results and Reports Recent Business
09 Nov 2022 //
PRNEWSWIRE
Biohaven fuels up for post-Pfizer future with $302M
09 Nov 2022 //
FIERCEBIOTECH
Biohaven plugs experimental trial with a flashy marketing video
24 Oct 2022 //
FIERCEPHARMA
Biohaven Announces Pricing of Public Offering of Common Shares
20 Oct 2022 //
PRNEWSWIRE
Biohaven Announces Launch of Public Offering of Common Shares
18 Oct 2022 //
NASDAQ
Biohaven raises OCD awareness using real patients in OCD trial ad campaign
14 Oct 2022 //
ENDPTS
Vlad Coric charts course for new Biohaven with neuroscience push
04 Oct 2022 //
ENDPTS
Pfizer Completes Acquisition of Biohaven Pharmaceuticals
04 Oct 2022 //
PRESS RELEASE
Biohaven flunks ALS trial, the 2nd gut punch since Nurtec sale
30 Sep 2022 //
FIERCEBIOTECH
Biohaven Announces Record Date for Anticipated Spin-Off
18 Sep 2022 //
BIOHAVENPHARMA
Big Pharma deal-making primed for acceleration
09 Aug 2022 //
EUROPEANPHARMACEUTICALREVIEW
Biohaven touts surge in Nurtec sales ahead of Pfizer takeover
06 Aug 2022 //
ENDPTS
Biohaven Reports Second Quarter 2022 Financial Results
05 Aug 2022 //
PRNEWSWIRE
Biohaven study links migraine and mental health; B+L bows TikTok challenge
02 Aug 2022 //
ENDPTS
More discussion needed on migraine, mental health link: survey
01 Aug 2022 //
FIERCEPHARMA
Biohaven Enrolls First Patient in PIII Trial of Taldefgrobep alfa in SMA
07 Jul 2022 //
PRNEWSWIRE
GCAR, Biohaven, Vigeo Commence Biohaven’s Troriluzole and Vigeo’S VT1021 Trial
06 Jul 2022 //
BUSINESSWIRE
